Background.dAlthough intensity modulation of the radiation beam has been shown to lower toxic effects for patients receiving whole-breast irradiation, relatively simple techniques may suffice. It is thus controversial whether such treatment justifies billing for intensity-modulated radiation therapy (IMRT).
Methods.dWe used the claims data to determine billing for IMRT With the changing health care climate in the United States, highquality, cost-effective cancer treatments that maximize efficacy while minimizing both acute and late toxicity are becoming increasingly important. Three prospective trials have demonstrated that IMRT improves dose homogeneity and decreases normal tissue toxicity compared with 2D radiotherapy. [1] [2] [3] It is worth noting that in these trials, the term "IMRT" refers to modulation of dose, whether using a forward-planning 3D treatment technique or an inverseplanning algorithm, which often requires additional time and effort for both the physician and physicist and is associated with specific billing codes that are reimbursed at a higher rate than forward-planning 3D treatmentplanning codes. Since it is well recognized that dose modulation decreases early and late toxicity, it is not surprising that Smith and colleagues found an increase over time in IMRT utilization, defined in this study by the IMRT common procedural terminology (CPT) codes. An interesting finding, however, was how IMRT utilization was influenced by the definition of "IMRT" in each geographic region. In some regions of the United States, the local coverage determination rendered by Medicare restricted the definition of IMRT treatment planning to those treatments in which inverse-planning algorithms were used, while in other regions "IMRT" allowed either inverseplanning or forward-planning 3D techniques to satisfy criteria for the IMRT CPT codes. The authors acknowledged that, unfortunately, they were not able to distinguish whether patients were treated with forward-planning or inverse-planning techniques because forward-planning intensity modulation does not have a unique CPT code. The results of the current study demonstrate the significant effect that reimbursement has on clinical practice and highlight the growing need for consistent definitions of treatment techniques and coverage policies.
In addition to financial costs and reimbursement, it is also important to consider the potential, but unknown, long-term risks of inverse-planning IMRT. While inverse-planning IMRT provides superior high-dose conformality, a greater volume of normal tissue may be exposed to low-dose radiation. Some experts suggest that the widespread use of IMRT in the past decade may result in a 2-fold increase in secondary malignancies, which is particularly worrisome for patients who are expected to have long-term survival. 4 There are some clinical situations, however, in which the cost-benefit ratio might favor inverseplanning IMRT. In particular, inverseplanning IMRT may provide superior target coverage of elective nodal regions, particularly the internal mammary nodal chain, while sparing the underlying heart and lung. Additionally, patients in whom the heart and lung lie particularly close to the chest wall may also benefit from inverseplanning IMRT.
Given the current state of the economy, it is reasonable to question how resources are allocated to optimize the quality of care while appropriately controlling health care costs. Smith and colleagues raise several important questions regarding how the radiation oncology community should incorporate more advanced technologies for breast cancer treatment and how the healthcare system, in general, should address variations in the definitions of and reimbursements for such techniques. This article is an important first step in defining and quantifying breast radiotherapy techniques and costs in the United States. It remains to be determined, however, how quality measures such as dose modulation should be reimbursed. Only scarce data are available on the utilisation rate of primary radiotherapy (RT) for patients with breast cancer. In this study, we compared the use of primary RT for patients with stages IeIII breast cancer in 4 of the 9 Dutch Comprehensive Cancer Centres, focussing specifically on time trends as well as age effects. From the populationbased cancer registries, we selected all females diagnosed with breast cancer between 1997 and 2008 (N ¼ 65,966, about 50% of all Dutch breast cancer patients in this period). We observed an overall increase in the use of primary RT for breast cancer patients ranging from 55e61% in 1997 to 58e68% in 2008. This can be explained by a higher rate of breast-conserving surgery (BCS), which was followed by RT in 87e99% of cases, and a reduced rate of total mastectomy (TM) which was followed by RT in 26e47% of cases. Increasing age was associated with a reduced use of RT, especially for those above 75. Finally, we observed a decrease in time of observed regional variances in the use of RT after BCS as well as after TM (for stage III disease). These findings can be attributed to the development and implementation of the Dutch nationwide guidelines for treatment of breast cancer.
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